Select Publications
Journal articles
2013, 'Research biopsies in the context of early phase oncology studies: clinical and ethical considerations', Oncology Reviews, pp. e5 - e5, http://dx.doi.org/10.4081/oncol.2013.232
,2013, 'The future is here: Tumour profiling in day-to-day clinical practice', Drug Discovery Today, 18, pp. 689 - 691, http://dx.doi.org/10.1016/j.drudis.2013.06.006
,2013, 'Combination molecularly targeted drug therapy in metastatic melanoma: Progress to date', Drugs, 73, pp. 767 - 777, http://dx.doi.org/10.1007/s40265-013-0049-8
,2013, 'Rationally Designed Drug Development beyond BRAF Inhibition in Metastatic Cutaneous Melanoma', World Journal of Cancer Research
,2013, 'Research biopsies in the context of early phase oncology studies: Clinical and ethical considerations', Oncology Reviews, 7, pp. 34 - 37, http://dx.doi.org/10.4081/oncol.2013.e5
,2012, 'DABRAFENIB MESYLATE Serine/Threonine-Protein Kinase B-raf Inhibitor, Oncolytic', DRUGS OF THE FUTURE, 37, pp. 469 - 474, http://dx.doi.org/10.1358/dof.2012.037.07.1820872
,2012, 'Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.', Journal of Clinical Oncology, 30, pp. 3000 - 3000, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3000
,2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours.', Journal of Clinical Oncology, 30, pp. e13585 - e13585, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13585
,2012, 'Advanced gastric cancer: Is there enough evidence to call second-line therapy standard?', World Journal of Gastroenterology, 18, pp. 6376 - 6378, http://dx.doi.org/10.3748/wjg.v18.i44.6376
,2012, 'Dabrafenib mesylate: Serine/threonine-protein kinase B-raf inhibitor oncolytic', Drugs of the Future, 37, pp. 469 - 474, http://dx.doi.org/10.1358/dof.2012.037.07.1820872
,2012, 'Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities', Clinical Medicine Insights: Oncology, 6, pp. 53 - 66, http://dx.doi.org/10.4137/CMO.S5855
,2012, 'The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: Rationale and latest evidence', Therapeutic Advances in Medical Oncology, 4, pp. 61 - 73, http://dx.doi.org/10.1177/1758834011432949
,2012, 'Dabrafenib. Serine/threonine-protein kinase B-raf inhibitor, Oncolitic.', Drugs of the Future, 37, pp. 469 - 469, http://dx.doi.org/10.1358/dof.2012.37.7.1820872
,2011, 'Biomarkers in advanced colorectal cancer: Challenges in translating clinical research into practice', Cancers, 3, pp. 1844 - 1860, http://dx.doi.org/10.3390/cancers3021844
,2011, 'IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.', Clinical Cancer Research, 17, pp. 2538 - 2548
,Conference Papers
2023, '760 Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a phase 1/2 study with MDNA11 in patients with advanced solid tumors', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, presented at SITC 38th Annual Meeting (SITC 2023) Abstracts, http://dx.doi.org/10.1136/jitc-2023-sitc2023.0760
,2022, 'A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680300998&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, '743 Pharmacokinetic and pharmacodynamic profile of a first-in-human study with MDNA11, an engineered long-acting beta-only IL-2 agonist', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, presented at SITC 37th Annual Meeting (SITC 2022) Abstracts, http://dx.doi.org/10.1136/jitc-2022-sitc2022.0743
,2022, '744 Interim single-agent safety and anti-tumor activity from dose escalation phase of ABILITY study on MDNA11, a long-acting beta-only IL-2 agonist', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, presented at SITC 37th Annual Meeting (SITC 2022) Abstracts, http://dx.doi.org/10.1136/jitc-2022-sitc2022.0744
,2021, 'A PHASE IB EXPANSION COHORT OF PIXATIMOD PLUS NIVOLUMAB IN PREVIOUSLY TREATED, MICROSATELLITE STABLE METASTATIC COLORECTAL CANCER (MSS MCRC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A367 - A367, http://dx.doi.org/10.1136/jitc-2021-SITC2021.341
,2021, 'A PHASE IB STUDY OF THE SAFETY AND TOLERABILITY OF PIXATIMOD PLUS NIVOLUMAB IN SUBJECTS WITH ADVANCED SOLID TUMORS WITH AN EXPANSION COHORT IN METASTATIC PANCREATIC ADENOCARCINOMA (MPDAC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A366 - A366, http://dx.doi.org/10.1136/jitc-2021-SITC2021.340
,2020, 'Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE (R)) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S507 - S507, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.869
,2020, 'A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368309070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), FL, Orlando, 07 December 2019 - 10 December 2019, http://dx.doi.org/10.1182/blood-2019-123921
,2018, 'Preliminary results from a Phase Ib study of pixatimod (PG545) in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, IRELAND, Dublin, pp. E18 - E19, presented at 30th EORTC-NCI-AACR Symposium, IRELAND, Dublin, 13 November 2018 - 16 November 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000461258600037&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'Conducting early-phase oncology clinical trials: Experience of a dedicated clinical trial unit', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 154 - 155, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200254&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2015, 'Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 57th Annual Meeting of the American-Society-of-Hematology, FL, Orlando, 05 December 2015 - 08 December 2015, http://dx.doi.org/10.1182/blood.V126.23.507.507
,2014, 'SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, ITALY, Milan, pp. 104 - 104, presented at 19th Congress of the European-Hematology-Association, ITALY, Milan, 12 June 2014 - 15 June 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342830900251&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.2620
,2014, 'A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.2514
,2014, 'Feasibility of circulating tumour cell (CTC) enumeration and molecular profiling (MP) as a biomarker in advanced endometrial cancer (aEC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5600
,2014, 'Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.8533
,2013, 'Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma', in BLOOD, AMER SOC HEMATOLOGY, LA, New Orleans, presented at 55th Annual Meeting of the American-Society-of-Hematology, LA, New Orleans, 07 December 2013 - 10 December 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000331385004173&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'The use of molecular profiling (MP) beyond standard panels in day-to-day practice: A multi-institutional multinational survey', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419604404&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours', in Journal of clinical oncology - official journal of the American Society of Clinical Oncology, American Society of Clinical Oncology, New York, pp. e13585 - e13585, presented at ASCO Annual Meeting, Chicago, USA, 01 June 2012 - 05 June 2012, http://meeting.ascopubs.org/gca?gca=ascomtg%3B30%2F15_suppl%2Fe13585&allch=&submit=Go#abstr-1
,2012, 'Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802283&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'Cardiac dysfunction in patients receiving trastuzumab for early stage breast cancer in the SESIAHS', in Aisa-Pacific Journal of Clinical Oncology, Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, presented at Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, 12 August 2010 - 14 August 2010, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2010.01301.x/epdf
,Conference Posters
2013, 'Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily pre-treated HER2-positive metastatic breast cancer', presented at San Antonio Breast Cancer Symposium, 10 December 2013 - 14 December 2013, http://www.abstracts2view.com/sabcs13/viewp.php?nu=P4-12-24
,2013, 'Patients' perceptions of research biopsies on early phase oncology trials', Liverpool UK, presented at NCRI Cancer Conference, Liverpool UK, 03 November 2013 - 06 November 2013
,2013, 'The use of molecular profiling (MP) beyond standard panels in day-to-day practice - a multi-institutional multi-national survey', Liverpool UK, presented at NCRI Cancer Conference, Liverpool UK, 03 November 2013 - 06 November 2013, http://conference.ncri.org.uk/abstracts/2013/abstracts/B101.htm
,2013, 'Clinical outcomes for patients in early phase clinical trials: the UCLH and Sarah Cannon Research UK experience', Liverpool UK, presented at NCRI Cancer Conference, Liverpool UK, 03 November 2013 - 06 November 2013, http://conference.ncri.org.uk/abstracts/2013/abstracts/B65.htm
,2010, 'Diffuse peritoneal adenomucinosis in a patient wiht familial adenomatous polyposis', Melbourne, Victoria, Australia, presented at Clinical Oncology Society of Australia Annual Scientific Meeting, Melbourne, Victoria, Australia, 09 November 2010 - 11 November 2010
,2009, 'Clear cell cancer of the ovary: from resistance to response', Canberra Australia, presented at MOGA Annual Scientific Meeting, Canberra Australia, 12 August 2009 - 14 August 2009, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2009.01218.x/pdf
,Conference Abstracts
2022, 'A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S1096 - S1096, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.1320
,2022, 'Abstract CT016: MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. CT016 - CT016, http://dx.doi.org/10.1158/1538-7445.am2022-ct016
,2022, 'A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3105 - 3105, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3105
,2022, 'First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 360490 - 360490, http://dx.doi.org/10.1200/jco.2022.40.36_suppl.360490
,2020, 'Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S722 - S722, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.1177
,